VIVITROL

Peak

naltrexone

NDAINTRAMUSCULARFOR SUSPENSION, EXTENDED RELEASEPriority Review
Approved
Apr 2006
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Clinical Trials (5)

NCT07064564Phase 1Not Yet Recruiting

iSTEP-N 101b: Pharmacokinetics and Safety Study of Low- and High-Dose Naltrexone Implants vs Monthly Vivitrol in Healthy Volunteers

Started Apr 2026
NCT06845124Phase 2Recruiting

A Trial to Investigate the Effects of Cannabidiol Plus Naltrexone on Alcohol Craving in Patients With Alcohol Dependence

Started Jul 2025
150 enrolled
Alcohol AddictionAlcoholism
NCT06620562Phase 4Recruiting

Improving Efficacity of Sleeve Gastrectomy With Naltrexone/Bupropion Extended-release Tablet

Started Jun 2025
NCT05304364Phase 1Completed

Safety, Tolerability, and Pharmacokinetics of Naltrexone Implant (DLP-160)

Started Mar 2022
NCT05028062Phase 4Recruiting

Naltrexone in AUD Reward Drinkers

Started Mar 2022

Loss of Exclusivity

LOE Date
Oct 15, 2029
44 months away
Patent Expiry
Oct 15, 2029

Patent Records (1)

Patent #ExpiryTypeUse Code
7919499
Oct 15, 2029
U-1123